Probably a bit off with your analysis. Keytruda is an immunotherapy drug (heading for US$10b this year) and the exercise is to investigate combination effect, which would massively enhance TT and Keytruda. TT would have a much much wider application, Keytruda would get a boost in efficacy. No one would be at loss if it goes well.
- Forums
- ASX - By Stock
- Qbiotics
Qbiotics, page-44
-
- There are more pages in this discussion • 1,199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online